Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00417209 · ClinicalTrials.gov registry record · Phase 3
Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 408
- Enrollment target
NCT00417209 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 408 participants.
The verdict
NCT00417209, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 408 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and the safety Larotaxel administered as single agent every 3 weeks to continuous administration of 5-FU every 3 weeks, in patients with advanced pancreatic cancer (non operable in a curative intent, locally recurrent or metastatic) previously treated with gemcitabine based therapy.
Interventions
- DRUG Capecitabine
- DRUG 5-Fluorouracil
- DRUG Larotaxel (XRP9881)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00417209
The ClinicalTrials.gov registry entry for NCT00417209 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 408 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Capecitabine is the first listed.
NCT00417209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00417209 about?
NCT00417209 is a clinical study titled "Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen". The purpose of this study is to compare the efficacy and the safety Larotaxel administered as single agent every 3 weeks to continuous administration of 5-FU every 3 weeks, in patients with advanced pancreatic cancer (non operable in a curative intent, locally recurrent or metastatic) previously tre...
What is the current status of trial NCT00417209?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 408 participants. The study started on 2006-12. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00417209?
The interventions under investigation include: Capecitabine (DRUG), 5-Fluorouracil (DRUG), Larotaxel (XRP9881) (DRUG).
Who is sponsoring clinical trial NCT00417209?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.